Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMHEAD: Temsirolimus in Relapsed/Recurrent HNSCC
NCT01172769Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Jun 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in head and neck squamous cell carcinoma (HNSCC), sponsored by Hannover Medical School. Primary endpoint: Progression Free Rate at 12 weeks. Started Jun 2010; status: completed.
02
Drugs
temsirolimus
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01172769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172769.